U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. ANDAs: Impurities in Drug Substances
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

ANDAs: Impurities in Drug Substances Guidance for Industry July 2009

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-1998-D-0021
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance provides revised recommendations on what chemistry, manufacturing, and controls (CMC) information to include regarding the reporting, identification, and qualification of impurities in drug substances produced by chemical synthesis when submitting: 

  • Original abbreviated new drug applications (ANDAs)
  • Drug master files (DMFs) including type II DMFs
  • ANDA supplements for changes in the synthesis or processing of a drug substance

The guidance also provides recommendations for establishing acceptance criteria for impurities in drug substances.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-1998-D-0021.

Back to Top